# US 2011/0301149 A1 · Compositions and methods for treating alcohol use disorders, pain and other diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301149 A1
- Document ID: US20110301149A1
- Status: Published application
- Kind: A1
- Application number: 13/123,399
- Filed: 2009-10-12
- Published: 2011-12-08
- Earliest claimed: 2008-10-10
- Assignees: Vm Discovery Inc.
- Inventors: Jay Jie-Qiang Wu
- Web page: https://patentgrep.com/patent/US20110301149A1

## CPC

- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07D 217/24: Oxygen atoms
- C07D 239/95: with hetero atoms directly attached in positions 2 and 4
- C07D 263/62: having two or more ring systems containing condensed 1,3-oxazole rings
- C07D 265/36: condensed with one six-membered ring
- C07D 279/16: condensed with one six-membered ring
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds which antagonize epsilon protein kinase C (PKCε). These compounds have a structural formula (Ia), (Ic) or (II). The present invention also provides pharmaceutical compositions containing these compounds and methods of treating various diseases, conditions, and/or symptoms by using these compounds.

## Claims

### Claim 1

A compound having a structural formula (Ia):
or a salt, solvate, or physiologically functional derivative thereof,
wherein:
X and Y are independently CR1R5, NR1, O or S, provided that at least one of X and Y is CR1R5 or NR1;
Z1 and Z2 are independently CHR2, NR2, O, or S;
A1, A2, A3, and A4 are independently CR3 or N;
each R1, R2, R3, and R5 is independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR7R8, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl;
R7 and R8 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R7 and R8, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring;
with the following provisos:
(a) at least one of Z1 and Z2 is CHR2 or NR2;
(b) at least one of A1, A2, A3, and A4 is CR3;
(c) at least one of R1, R2, R3 and R5 is not hydrogen;
(d) when R1 and R5 are independently hydrogen, aryl or substituted aryl; R2 is hydrogen, arylalkyl or substituted arylalkyl; then R3 is not aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
(e) when R3 is —C(O)NR7R8; R2 is hydrogen or substituted arylalkyl; then at least one of R1 and R5 is not halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, alkyl, or substituted alkyl; and
(f) when R3 is —C(O)NR7R8; R7 is hydrogen; R8 is substituted alkyl, arylalkyl, substituted arylalkyl, heteroaryl, heteroalkyl or substituted aryl; R2 is hydrogen or substituted arylalkyl; then at least one R1 is not halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, alkyl, or substituted alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Z2 is NR2; and Y is O or S.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Z2 is NR2; Y is O or S; X is CR1R5; and Z1 is O or S.

### Claim 4 (depends on 3)

The compound of claim 3, having a structural formula (Ih).
wherein.
A1, A2, A3, and A4 are independently CR3 or N;
each R3 and R5 is independently hydrogen halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR7R8, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl;
R7 and R8 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R7 and R8, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring;
Z11 and Y11 are independently O or S;
R2, R11 and R12 are independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, —C(O)NR7R8, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl or substituted heteroalkyl, or alternatively, R11 and R12, taken together with atoms to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloalkyl or cycloheteroalkyl ring.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R12 is —C(O)NR7R8;

### Claim 6 (depends on 4)

The compound of claim 4, which is selected from the group consisting of
ID
IUPAC Name
435
4-{(Z/E)-[4-(cyclohexylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-
ylidene]methyl}-N-[2-(2-methylpiperidin-1-yl)ethyl]benzamide;
481
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-[3-(pyrrolidin-1-yl)propyl]benzamide;
483
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-ylidene]methyl}-N-
[3-(pyrrolidin-1-yl)propyl]benzamide hydrate;
485
N-[3-(azepan-1-yl)propyl]-4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzothiazin-2-ylidene]methyl}benzamide;
801
4-[(Z/E)-{3-oxo-4-[2-(trifluoromethyl)benzyl]-3,4-dihydro-2H-1,4-benzoxazin-2-
ylidene}methyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide;
805
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-{[2-(pyrrolidin-1-yl)cyclopropyl]methyl}benzamide;
807
4-{(Z/E)-[4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-{3-[4-(pyridin-4-yl)piperazin-1-yl]propyl}benzamide;
811
N-[3-(azepan-1-yl)propyl]-4-{(Z/E)-[4-(1,3-benzodioxol-5-ylmethyl)-3-oxo-3,4-dihydro-
2H-1,4-benzoxazin-2-ylidene]methyl}benzamide;
815
(2Z/2E)-4-(2-fluorobenzyl)-2-({1-oxo-2-[3-(pyrrolidin-1-yl)propyl]-1,2-
dihydroisoquinolin-6-yl}methylidene)-2H-1,4-benzoxazin-3(4H)-one;
817
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-ylidene]methyl}-N-
(octahydroisoquinolin-2(1H)-ylmethyl)benzamide;
819
N-[(4-cyclohexylpiperidin-1-yl)methyl]-4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-
2H-1,4-benzoxazin-2-ylidene]methyl}benzamide;
821
N-[3-(azepan-1-yl)propyl]-4-{(1Z/1E)-1-[4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzoxazin-2-ylidene]ethyl}benzamide;
825
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-[3-(pyridin-4-yl)propyl]benzamide;
827
4-[(1Z/1E)-1-{4-[4-(morpholin-4-yl)benzyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-
ylidene}ethyl]-N-[3-(morpholin-4-yl)propyl]benzamide;
829
N-4-{(1Z/1E)-1-[4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-
ylidene]ethyl}-N-[3-(morpholin-4-yl)propyl]benzamide;
831
N-[3-(azepan-1-yl)propyl]-4-[(Z/E)-{4-[2,4-bis(trifluoromethyl)benzyl]-3-oxo-3,4-
dihydro-2H-1,4-benzothiazin-2-ylidene}methyl]benzamide;
837
4-{(1Z/1E)-1-[4-(2,4-difluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-
ylidene]ethyl}-N-[3-(morpholin-4-yl)propyl]benzamide;
839
4-{(1Z/1E)-1-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-ylidene]ethyl}-
N-[3-(pyrrolidin-1-yl)propyl]benzamide; and
841
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-ylidene]methyl}-N-
methyl-N-[3-(morpholin-4-yl)propyl]benzamide;
or a salt, solvate, or physiologically functional derivative thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound, or a salt, solvate, or physiologically functional derivative thereof; and at least one pharmaceutically acceptable vehicle; wherein the compound is a compound of Claim 1 or selected from the group consisting of
ID
IUPAC Name
301
4-{(Z/E)-[4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
(3-pyrrolidin-1-ylpropyl)benzamide;
307
N-{2-[cyclohexyl(methyl)amino]ethyl}-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-
2H-1,4-benzoxazin-2-ylidene]methyl}benzamide;
309
4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-ylidene]methyl}-N-
(2-pyrrolidin-1-ylethyl)benzamide;
311
N-[3-(2-ethylpiperidin-1-yl)propyl]-4-{(Z/E)-[4-(2-methylbenzyl)-3-oxo-3,4-dihydro-2H-
1,4-benzothiazin-2-ylidene]methyl}benzamide;
315
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
(2-pyrrolidin-1-ylethyl)benzamide;
321
4-{(Z/E)-[4-(2,5-dimethylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-
ylidene]methyl}-N-[3-(2-ethylpiperidin-1-yl)propyl]benzamide;
323
N-(2-azepan-1-ylethyl)-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzothiazin-2-ylidene]methyl}benzamide;
325
N-[(1-ethylpyrrolidin-2-yl)methyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-
1,4-benzoxazin-2-ylidene]methyl}benzamide;
327
(2Z/2E)-N-[3-(4-benzylpiperidin-1-yl)propyl]-4-(3-methylbenzyl)-3-oxo-2-
(phenylmethylidene)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide;
329
N-[2-(dimethylamino)ethyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzoxazin-2-ylidene]methyl}benzamide:
331
N-{3-[cyclohexyl(methyl)amino]propyl}-4-{(Z/E)-[4-(2-methylbenzyl)-3-oxo-3,4-dihydro-
2H-1,4-benzothiazin-2-ylidene]methyl}benzamide;
339
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
[2-(dibutylamino)ethyl]benzamide;
341
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
{3-[cyclohexyl(methyl)amino]propyl}benzamide;
343
N-[(1-ethylpyrrolidin-2-yl)methyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-
1,4-benzothiazin-2-ylidene]methyl}benzamide;
347
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
[(1-ethylpyrrolidin-2-yl)methyl]benzamide;
351
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
[3-(2-ethylpiperidin-1-yl)propyl]benzamide;
353
N-[3-(dipropylamino)propyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzothiazin-2-ylidene]methyl}benzamide;
361
N-[3-(2-ethylpiperidin-1-yl)propyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-
1,4-benzothiazin-2-ylidene]methyl}benzamide;
363
4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-(3-pyrrolidin-1-ylpropyl)benzamide;
365
(2Z/2E)-N-(2-azepan-1-ylethyl)-4-(4-fluorobenzyl)-3-oxo-2-(phenylmethylidene)-3,4-
dihydro-2H-1,4-benzothiazine-6-carboxamide;
375
N-{3-[benzyl(methyl)amino]propyl}-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-
1,4-benzothiazin-2-ylidene]methyl}benzamide;
377
4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-N-
[3-(3-methylpiperidin-1-yl)propyl]benzamide;
379
N-(2-azepan-1-ylethyl)-4-{(Z/E)-[4-(3-chlorobenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzothiazin-2-ylidene]methyl}benzamide;
383
N-[2-(dipropylamino)ethyl]-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-
benzothiazin-2-ylidene]methyl}benzamide;
387
4-{(Z/E)-[4-(2,5-dimethylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-
ylidene]methyl}-N-[2-(2-methylpiperidin-1-yl)ethyl]benzamide;
393
N-{3-[cyclohexyl(methyl)amino]propyl}-4-{(Z/E)-[4-(3-methylbenzyl)-3-oxo-3,4-dihydro-
2H-1,4-benzothiazin-2-ylidene]methyl}benzamide;
395
4-{(Z/E)-[4-(2-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-(2-pyrrolidin-1-ylethyl)benzamide; and
209
4-{(Z/E)-[4-(2-methylbenzyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-ylidene]methyl}-
N-[3-(3-methylpiperidin-1-yl)propyl]benzamide.

### Claim 8

A compound having a structural formula (II),
or a salt, solvate, or physiologically functional derivative thereof,
wherein:
A is N or CH;
B is a 5-, 6-, or 7-membered cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl ring;
D is NR4, S, or O;
R1, R2, R3, and R4 are independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl;
R5 and R6 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R5 and R6, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring; and
X is —CH2—, CH2—O—, —CH2—S—, —O— or —S—.

### Claim 9 (depends on 8)

The compound of claim 8, wherein A is N; and D is O.

### Claim 10 (depends on 8)

The compound of claim 8, wherein A is N; D is O; and R3 is benzyl or substituted benzyl.

### Claim 11 (depends on 10)

The compound of claim 10 having a structural formula (IIa).
wherein:
R1 and R2 are independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl:
R5 and R6 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively, R5 and R6, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring:
X is —CH2—, —CH2—O—, —CH2—S—, —O— or —S—;
Z1 and Z2 are independently CR12 and N; and
R12 is selected from hydrogen, alkyl, substituted alkyl;
n is an integer from 0 to 5;
m is an integer from 0 to 8; and
each R11 and R13 is independently selected from the group consisting of halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, and substituted heteroalkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R1 is —C(O)NR5R6.

### Claim 13 (depends on 11)

The compound of claim 11, which is selected from the group consisting of
ID
IUPAC Name
901
N-[3-(azepan-1-yl)propyl]-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
903
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(3,5-dimethylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
905
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[2-(2-methylpiperidin-1-
yl)ethyl]piperidine-4-carboxamide;
907
N-[3-(4-benzylpiperidin-1-yl)propyl]-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
909
N-{2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl}-1-{[2-(4-ethylphenyl)-5-methyl-1,3-
oxazol-4-yl]methyl}piperidine-4-carboxamide;
911
N-{3-[4-(3-chlorobenzyl)piperidin-1-yl]propyl}-1-{[2-(3-chlorophenyl)-5-methyl-1,3-
oxazol-4-yl]methyl}piperidine-4-carboxamide;
913
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-[4-(4-
fluorophenyl)piperazin-1-yl]propyl}piperidine-4-carboxamide;
915
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-[4-(2-
fluorophenyl)piperazin-1-yl]propyl}piperidine-3-carboxamide;
919
N-(2,4-difluorophenyl)-4-{5-methyl-4-[(4-phenylpiperazin-1-yl)methyl]-1,3-oxazol-2-
yl}benzamide;
929
N-[3-(azepan-1-yl)propyl]-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-
methylpiperidine-4-carboxamide;
931
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-[4-(pyridin-4-
yl)piperidin-1-yl]propyl}piperidine-4-carboxamide;
933
N-{[2-(azepan-1-yl)cyclopropyl]methyl}-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
935
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(morpholin-4-
yl)propyl]piperidine-4-carboxamide;
937
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(4-cyclohexylpiperazin-1-
yl)propyl]piperidine-4-carboxamide;
939
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(piperidin-1-yl)-2-
(piperidin-1-ylmethyl)propyl]piperidine-4-carboxamide:
941
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(1,4-dioxa-8-
azaspiro[4.5]dec-8-yl)propyl]piperidine-4-carboxamide;
943
N-[3-(azepan-1-yl)propyl]-1-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-
yl}methyl)piperidine-4-carboxamide;
945
N-[3-(azepan-1-yl)propyl]-1-{[5-methyl-2-(pyridin-4-yl)-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
947
N-[3-(azepan-1-yl)propyl]-1-{[2-(2,4-difluorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
949
N-[3-(azepan-1-yl)propyl]-1-{[2-(1,3-benzodioxol-5-yl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
951
N-[3-(azepan-1-yl)propyl]-1-{[2-(2,4-dimethoxyphenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
953
N-[3-(azepan-1-yl)propyl]-1-{[2-(4-benzylphenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
955
N-[3-(azepan-1-yl)propyl]-1-({2-[4-(dimethylcarbamoyl)phenyl]-5-methyl-1,3-oxazol-4-
yl}methyl)piperidine-4-carboxamide;
957
N-[3-(azepan-1-yl)propyl]-1-({5-methyl-2-[4-(piperidin-1-yl)phenyl]-1,3-oxazol-4-
yl}methyl)piperidine-4-carboxamide;
959
N-[3-(azepan-1-yl)propyl]-1-{[5-methyl-2-(naphthalen-1-yl)-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
961
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(3-{methyl[4-(morpholin-4-
yl)benzyl]amino}propyl)piperidine-4-carboxamide;
963
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(3-{[(4-
methoxyphenyl)carbonyl]amino}propyl)piperidine-4-carboxamide;
965
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[4-(4-methylpiperazin-1-
yl)phenyl]piperidine-4-carboxamide;
967
N-(1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}piperidin-4-yl)-5-(piperidin-
1-yl)pyridin-2-amine; and
969
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-4-[4-(piperidin-1-
yl)phenyl]piperazine;
or a salt, solvate;, or physiologically functional derivative thereof.

### Claim 14 (depends on 10)

The compound of claim 10 having a structural formula (IIb).
wherein:
R1 and R2 are independently hydrogen, halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl:
R5 and R6 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, or substituted heteroalkyl, or alternatively. R5 and R6, taken together with the nitrogen atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring;
X is —CH2—, —CH2—O—, —CH2—S—, —O— or —S—;
n is an integer from 0 to 5;
m is an integer from 0 to 4; and
each R11 and R13 is independently selected from the group consisting of halogen, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, —C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heteroalkyl, and substituted heteroalkyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R1 is —C(O)NR5R6.

### Claim 16 (depends on 14)

The compound of claim 14, which is selected from the group consisting of
ID
IUPAC Name
543
N-[2-(4-ethylpiperazin-1-yl)ethyl]-4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-
yl}benzamide;
523
4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-yl}-N-[3-(4-methylpiperazin-1-
yl)propyl]benzamide;
563
4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-yl)-N-[3-(4-
methylpiperazin-1-yl)propyl]benzamide;
565
4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-yl}-N-[3-(4-propylpiperazin-1-
yl)propyl]benzamide;
569
N-(2-azepan-1-ylethyl)-4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-
yl)benzamide;
571
4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-yl)-N-[2-(4-
methylpiperazin-1-yl)ethyl]benzamide;
573
N-(2-azepan-1-ylethyl)-4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-
yl}benzamide;
591
4-[5-methyl-4-(phenoxymethyl)-1,3-oxazol-2-yl]-N-[3-(4-methylpiperazin-1-
yl)propyl]benzamide;
593
N-[2-(4-ethylpiperazin-1-yl)ethyl]-4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-
oxazol-2-yl)benzamide; and
917
N-{3-[4-(4-fluorophenyl)piperazin-1-yl]propyl}-4-{5-methyl-4-[(4-
methylphenoxy)methyl]-1,3-oxazol-2-yl}benzamide;
or a salt, solvate, or physiologically functional derivative thereof.

### Claim 17 (depends on 8)

A pharmaceutical composition comprising a therapeutically effective amount of a compound, or a salt, solvate, or physiologically functional derivative thereof; and at least one pharmaceutically acceptable vehicle; wherein the compound is a compound of claim 8 or is selected from the group consisting of
ID
IUPAC Name
503
N-(2-azepan-1-ylethyl)-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
505
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(3-methylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
507
1-{[2-(4-chlorophenyl)-5-methy-1,3-oxazol-4-yl]methyl}-N-[3-(2-ethylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
509
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[2-(2-methylpiperidin-1-
yl)ethyl]piperidine-4-carboxamide;
511
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-
[ethyl(phenyl)amino]ethyl}piperidine-4-carboxamide;
513
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-
[methyl(phenyl)amino]propyl}piperidine-4-carboxamide;
515
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-
[ethyl(phenyl)amino]ethyl}piperidine-4-carboxamide;
517
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-
[ethyl(phenyl)amino]ethyl}piperidine-3-carboxamide;
519
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-
[ethyl(phenyl)amino]ethyl}piperidine-3-carboxamide;
521
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-
[methyl(phenyl)amino]propyl}piperidine-3-carboxamide;
523
4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-yl}-N-[3-(4-methylpiperazin-1-
yl)propyl]benzamide;
525
N-{3-[benzyl(methyl)amino]propyl}-1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
527
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(3,5-dimethylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
529
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-[methyl(2-
phenylethyl)amino]ethyl}piperidine-4-carboxamide;
531
1-{[5-methyl-2-(2-methylphenyl)-1,3-oxazol-4-yl]methyl}-N-[3-(3-methylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
533
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(3,5-dimethylpiperidin-1-
yl)propyl]piperidine-4-carboxamide;
535
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-
(cyclohexylsulfanyl)propyl]piperidine-4-carboxamide;
537
N-{2-[ethyl(phenyl)amino]ethyl}-1-{[2-(2-fluorophenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
539
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{2-[methyl(2-
phenylethyl)amino]ethyl}piperidine-3-carboxamide;
541
1-{[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methyl}-N-[2-(4-methylpiperidin-1-
yl)ethyl]piperidine-4-carboxamide;
543
N-[2-(4-ethylpiperazin-1-yl)ethyl]-4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-
yl}benzamide;
545
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[2-(4-ethylpiperazin-1-
yl)ethyl]piperidine-4-carboxamide;
547
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(4-methylpiperazin-1-
yl)propyl]piperidine-4-carboxamide;
549
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-(4-methylpiperazin-1-
yl)propyl]piperidine-3-carboxamide;
551
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[2-(4-ethylpiperazin-1-
yl)ethyl]piperidine-3-carboxamide;
553
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(3-pyrrolidin-1-
ylpropyl)piperidine-4-carboxamide;
555
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(3-pyrrolidin-1-
ylpropyl)piperidine-4-carboxamide;
557
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(3-pyrrolidin-1-
ylpropyl)piperidine-3-carboxamide;
559
1-{[5-methyl-2-(2-methylphenyl)-1,3-oxazol-4-yl]methyl}-N-{3-
[methyl(phenyl)amino]propyl}piperidine-4-carboxamide;
561
1-{[2-(3-bromophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-[3-
(cyclohexylsulfanyl)propyl]piperidine-4-carboxamide;
563
4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-yl)-N-[3-(4-
methylpiperazin-1-yl)propyl]benzamide;
565
4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-yl}-N-[3-(4-propylpiperazin-1-
yl)propyl]benzamide;
567
1-{[5-methyl-2-(4-propoxyphenyl)-1,3-oxazol-4-yl]methyl}-N-(pyridin-3-
ylmethyl)piperidine-4-carboxamide;
569
N-(2-azepan-1-ylethyl)-4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-
yl)benzamide;
571
4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-oxazol-2-yl)-N-[2-(4-
methylpiperazin-1-yl)ethyl]benzamide;
573
N-(2-azepan-1-ylethyl)-4-{5-methyl-4-[(phenylsulfanyl)methyl]-1,3-oxazol-2-yl}benzamide
575
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-{3-[ethyl(3-
methylphenyl)amino]propyl}piperidine-4-carboxamide;
577
1-{[5-methyl-2-(4-propoxyphenyl)-1,3-oxazol-4-yl]methyl}-N-(pyridin-2-
ylmethyl)piperidine-4-carboxamide;
579
N-{3-[cyclohexyl(methyl)amino]propyl}-1-{[5-methyl-2-(2-methylphenyl)-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
581
N-[2-(4-chlorophenyl)ethyl]-1-{[2-(4-ethylphenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
583
N-{2-[ethyl(phenyl)amino]ethyl}-1-{[2-(4-ethylphenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-4-carboxamide;
585
N-[3-(cyclohexylsulfanyl)propyl]-1-{[5-methyl-2-(2-methylphenyl)-1,3-oxazol-4-
yl]methyl}piperidine-3-carboxamide;
587
N-[2-(4-chlorophenyl)ethyl]-1-{[2-(4-ethylphenyl)-5-methyl-1,3-oxazol-4-
yl]methyl}piperidine-3-carboxamide;
589
N-[2-(4-benzylpiperazin-1-yl)ethyl]-2-({[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-
yl]methyl}sulfanyl)acetamide;
591
4-[5-methyl-4-(phenoxymethyl)-1,3-oxazol-2-yl]-N-[3-(4-methylpiperazin-1-
yl)propyl]benzamide;
593
N-[2-(4-ethylpiperazin-1-yl)ethyl]-4-(5-methyl-4-{[(4-methylphenyl)sulfanyl]methyl}-1,3-
oxazol-2-yl)benzamide;
595
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(pyridin-3-
ylmethyl)piperidine-4-carboxamide;
597
1-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(2-pyrrolidin-1-
ylethyl)piperidine-4-carboxamide; and
599
1-{[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-N-(2-pyrrolidin-1-
ylethyl)piperidine-4-carboxamide.

### Claim 18 (depends on 1, 8)

A method of treating a disease, disorder, symptom, or condition associated with irregular PKCε activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or 8, or a salt, solvate, or physiologically functional derivative thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease, disorder, symptom or condition is selected from the group consisting of acute pain, chronic pain, inflammatory pain, neuropathic pain, diabetic neuropathy, alcoholic polyneuropathy, cancer- or chemotherapy-induced pain, a generalized pain disorder, tonic pain, persistent pain, postoperative pain, chemical-induced pain, drug-induced pain, migraine, anxiety, skeletal muscle spasms, convulsive seizures, epilepsy, alcohol abuse and alcoholism associated disease, insomnia, pain associated with alcohol-induced hyperalgesia, type 1 and type 2 diabetes, hepatic steatosis or liver cirrhosis, bipolar disorder, mania, sleeping disorder, burn, posttraumatic stress disorder, cardiac disorder, smoking, inflammation and immune-mediated disorders (including microbial infection and organ transplantation), cancer (including breast, head and neck, prostate and lung cancer), and a combination thereof.

### Claim 20 (depends on 18)

The method of claim 18, wherein the disease, disorder, symptom or condition is cancer or cancer-induced pain.

### Claim 21 (depends on 18)

The method of claim 18, wherein the disease, disorder, symptom or condition is associated with maladaptive substance use, substance dependence, alcohol use or abuse, substance use or abuse, drug use or abuse, or drug-related effect, or a combination thereof.

### Claim at position 22

22-24. (canceled)

### Claim 25 (depends on 7, 17)

The pharmaceutical composition of claim 7 or 17, wherein the compound inhibits PKCε reversibly with an IC50 of less than about 1 μM.

### Claim 26 (depends on 7, 17)

The pharmaceutical composition of claim 7 or 17, wherein the compound inhibits PKCε non-competitively with ATP.

### Claim 27 (depends on 7, 17)

The pharmaceutical composition of claim 7 or 17, wherein the compound of is selective for PKCε.

### Claim 28

(canceled)
